See insights on WuXi AppTec including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The board of directors (the “Board”) of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開 發股份有限公司) (the “Company” together with its subsidiaries, the “Group”) hereby announces that a meeting of the Board will be held on Thursday, August 13, 2020 for the On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006. The financial
Wuxi Apptec, Inc. is located in Saint Paul, MN, United States and is part of the Pharmaceutical Manufacturing Industry. WuXi Biologics is a Chinese headquartered organization that provides open-access, integrated technology platforms for biologics drug development. WuXi AppTec’s Honk Kong IPO valued WuXi’s former subsidiary at $10.2 billion, approximately three times the value Defendants paid for the entire Company barely two years prior. "Our new U.S. based presence with a highly experienced scientific and production team is another step towards better enabling our partners through added capacity, greater flexibility, and our customer-centric approach to drug development and manufacturing services." In the same year, WuXi acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. April 29, 2020. WuXi AppTec's STA Subsidiary Opens Operations in San Diego News provided by. "WuXi's open-access capability and technology platform strives to enable anyone and any company to discover and develop healthcare products more efficiently and cost effectively," said Dr. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. WuXi AppTec Wuhan Site Resumes Operation. Share this article. There are 5 areas of focus for services: WuXi AppTec has 17,730 employees across 10 locations. WuXi AppTec Aug 08, 2016, 08:00 ET. WuXi AppTec Reports Strong 2019 Annual Results. All Rights Reserved. There are 11 companies in the Wuxi Apptec…
In 2015, WuXi completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited.
Share this article. WuXi AppTec founder Ge Li took the U.S.-listed company private in 2015 at a valuation of $3.3 billion. WuXi's founder is Dr. Ge Li, an organic chemist, who founded WuXi PharmaTech in Shanghai in December 2000. EX-8.1 2 d237986dex81.htm LIST OF SUBSIDIARIES Exhibit 8.1 . We provide Phase I to Phase IV clinical development services & BE (Bioequivalence) , for products including pharmaceuticals, biologics, and medical devices. As a result of the merger, New WuXi Life Science Limited acquired the Company in a cash transaction valued at approximately US$3.3 billion. WuXi established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." The company opened … EX-8.1 2 dex81.htm LIST OF SUBSIDIARIES Exhibit 8.1 . WuXi AppTec Reports Solid First-Quarter 2020 Results. March 12, 2020. STA Pharmaceutical Co., Ltd., a WuXi AppTec company (WuXi STA), is a global leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with operations in China and the United States. February 12, 2020. The company began a biologics discovery, development, and manufacturing operation in In 2014, WuXi opened a new biologics biosafety testing facility in Suzhou. WuXi AppTec Aug 08, 2016, 08:00 ET. CTRL + SPACE for auto-complete. As an innovation-driven and customer-focused company, WuXiAppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.